A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
Glioblastoma (GBM) is one of the most common primary and deadliest malignant brain tumor with chemoresistance and poor prognosis. There is a lack of effective chemotherapeutic drug for the treatment of GBM. In this work, we reported the preparation of a histone deacetylase (HDAC) inhibitor, DMC-HA,...
Main Authors: | Hao Wang, Lei Shi, Zhimin Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.756817/full |
Similar Items
-
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
by: Marinella Zilli, et al.
Published: (2013-07-01) -
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
by: Anton Frühauf, et al.
Published: (2021-08-01) -
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
by: Flávia Alves Verza, et al.
Published: (2020-06-01) -
The application of histone deacetylases inhibitors in glioblastoma
by: Rui Chen, et al.
Published: (2020-07-01) -
Hydroxamic acid - A novel molecule for anticancer therapy
by: Dilipkumar Pal, et al.
Published: (2012-01-01)